DSIP

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.252

Reference number

5mg

Lyophilized vial

Origin

DSIP (Delta Sleep-Inducing Peptide) was first isolated in 1974 by Schoenenberger and Monnier from the cerebral venous blood of rabbits subjected to low-frequency electrical stimulation of the thalamus. The peptide was named for its ability to promote delta-wave (slow-wave) sleep patterns in the EEG of recipient animals.

Research Lineage

Graf and Kastin conducted the primary characterization of DSIP's distribution and metabolism. Subsequent research expanded beyond sleep to include stress response, pain modulation, and neuroendocrine regulation. Prudchenko et al. studied its analogs for improved stability. DSIP has been investigated in clinical studies in Europe for sleep disorders and alcohol withdrawal, though it lacks formal drug approval.

Mechanism of Action

DSIP's mechanism of action is not fully characterized despite decades of research. It has been observed to modulate corticotropin and LH secretion, interact with opioid receptors, and influence monoamine oxidase activity. Its effects on sleep architecture involve promotion of delta-wave EEG patterns without the sedation profile of benzodiazepines. Research suggests it acts as a modulatory neuropeptide rather than a classical receptor agonist.

Structural Notes

Nonapeptide. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Molecular weight: 848.82 Da. Unusually, it contains no basic amino acid residues.